Ann Surg Treat Res.  2014 Aug;87(2):94-99. 10.4174/astr.2014.87.2.94.

Pancreaticoduodenectomy for secondary periampullary cancer following extrahepatic bile duct cancer resection

• Kim DH
• Choi DW
• Choi SH
• Heo JS

• KMID: 1882837
• DOI: http://doi.org/10.4174/astr.2014.87.2.94

Abstract

PURPOSE
This study addressed the feasibility and effect of surgical treatment of metachronous periampullary carcinoma after resection of the primary extrahepatic bile duct cancer. The performance of this secondary curative surgery is not well-documented.
METHODS
We reviewed, retrospectively, the medical records of 10 patients who underwent pancreaticoduodenectomy (PD) for secondary periampullary cancer following extrahepatic bileduct cancer resection from 1995 to 2011.
RESULTS
The mean age of the 10 patients at the second operation was 61 years (range, 45-70 years). The primary cancers were 7 hilar cholangiocarcinomas, 2 middle common bile duct cancers, and one cystic duct cancer. The secondary cancers were 8 distal common bile duct cancers and 2 carcinomas of the ampulla of Vater. The second operations were 6 Whipple procedures and 4 pylorus-preserving pancreaticoduodenectomies. The mean interval between primary treatment and metachronous periampullary cancer was 20.6 months (range, 3.4-36.6 months). The distal resection margin after primary resection was positive for high grade dysplasia in one patient. Metachronous tumor was confirmed by periampullary pathology in all cases. Four of the 10 patients had delayed gastric emptying (n = 2) or pancreatic fistula (n = 2) after reoperation. There were no perioperative deaths. Median survival after PD was 44.6 months (range, 8.5-120.5 months).
CONCLUSION
Based on the postoperative survival rate, PD may provide an acceptable protocol for resection in patients with metachronous periampullary cancer after resection of the extrahepatic bile duct cancer.

Keyword

Extrahepatic bile duct; Cholangiocarcinoma; Metachronous neoplasms; Pancreaticoduodenectomy

MeSH Terms

Ampulla of Vater
Bile Ducts, Extrahepatic*
Cholangiocarcinoma
Common Bile Duct
Cystic Duct
Gastric Emptying
Humans
Medical Records
Neoplasms, Second Primary
Pancreatic Fistula
Pancreaticoduodenectomy*
Pathology
Reoperation
Retrospective Studies
Survival Rate

Figure

• 

  Fig. 1 Overall survival rates (A) after extrahepatic bile duct resection and (B) after pancreaticoduodenectomy for secondary periampullary cancer.

Reference

1. Lindell G, Hansson L, Dawiskiba S, Andersson R, Axelson J, Ihse I. Operations for extrahepatic bile duct cancers: are the results really improving? Eur J Surg. 2000; 166:535–539.

2. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009; 16:1–7.

3. Hori H, Ajiki T, Fujita T, Okazaki T, Suzuki Y, Kuroda Y, et al. Double cancer of gall bladder and bile duct not associated with anomalous junction of the pancreaticobiliary duct system. Jpn J Clin Oncol. 2006; 36:638–642.

4. Kurosaki I, Watanabe H, Tsukada K, Hatakeyama K. Synchronous primary tumors of the extrahepatic bile duct and gallbladder. J Surg Oncol. 1997; 65:258–262.

5. Gertsch P, Thomas P, Baer H, Lerut J, Zimmermann A, Blumgart LH. Multiple tumors of the biliary tract. Am J Surg. 1990; 159:386–388.

6. Fujii T, Kaneko T, Sugimoto H, Okochi O, Inoue S, Takeda S, et al. Metachronous double cancer of the gallbladder and common bile duct. J Hepatobiliary Pancreat Surg. 2004; 11:280–285.

7. Merenda R, Portale G, Sturniolo GC, Marciani F, Faccioli AM, Ancona E. A rare surgical case of metachronous double carcinoma of the biliary tract. Scand J Gastroenterol. 2007; 42:1265–1268.

8. Joo HJ, Kim GH, Jeon WJ, Chae HB, Park SM, Youn SJ, et al. Metachronous bile duct cancer nine years after resection of gallbladder cancer. World J Gastroenterol. 2009; 15:3440–3444.

9. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005; 138:8–13.

10. Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H, et al. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg. 2002; 9:569–575.

11. Warren S, Gates O. Multiple primary malignant tumors: a survey of literature and statistical study. Am J Cancer. 1932; 16:1358–1414.

12. Kobayashi S, Konishi M, Kato Y, Gotohda N, Takahashi S, Kinoshita T, et al. Surgical outcomes of multicentric adenocarcinomas of the biliary tract. Jpn J Clin Oncol. 2011; 41:1079–1085.

13. Ogura Y, Takahashi K, Tabata M, Mizumoto R. Clinicopathological study on carcinoma of the extrahepatic bile duct with special focus on cancer invasion on the surgical margins. World J Surg. 1994; 18:778–784.

14. Komi N, Takehara H, Kunitomo K. Choledochal cyst: anomalous arrangement of the pancreaticobiliary ductal system and biliary malignancy. J Gastroenterol Hepatol. 1989; 4:63–74.

15. Hasumi A, Matsui H, Sugioka A, Uyama I, Komori Y, Fujita J, et al. Precancerous conditions of biliary tract cancer in patients with pancreaticobiliary maljunction: reappraisal of nationwide survey in Japan. J Hepatobiliary Pancreat Surg. 2000; 7:551–555.

16. Okamura K, Hayakawa H, Kuze M, Takahashi H, Kosaka A, Mizumoto R, et al. Triple carcinomas of the biliary tract associated with congenital choledochal dilatation and pancreaticobiliary maljunction. J Gastroenterol. 2000; 35:465–471.

17. Kasuya K, Nagakawa Y, Matsudo T, Ozawa T, Tsuchida A, Aoki T, et al. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 2009; 16:376–381.

18. Funabiki T, Matsubara T, Miyakawa S, Ishihara S. Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg. 2009; 394:159–169.

19. Yoon YS, Kim SW, Jang JY, Park YH. Curative reoperation for recurrent cancer of the extrahepatic bile duct: report of two cases. Hepatogastroenterology. 2005; 52:381–384.

20. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992; 70:1498–1501.

21. Hoang MP, Murakata LA, Katabi N, Henson DE, Albores-Saavedra J. Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol. 2002; 15:1251–1258.

22. Okamoto A, Tsuruta K, Matsumoto G, Takahashi T, Kamisawa T, Egawa N, et al. Papillary carcinoma of the extrahepatic bile duct: characteristic features and implications in surgical treatment. J Am Coll Surg. 2003; 196:394–401.

23. Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 2012; 83:83–90.

24. Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997; 15:947–954.

25. Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg. 2000; 7:128–134.

26. Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J Hepatobiliary Pancreat Surg. 2000; 7:115–121.

27. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996; 83:1712–1715.

28. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery: a series of 112 cases. Ann Surg Oncol. 2007; 14:1212–1219.

29. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245:755–762.